Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-992.95%
operating margin TTM
-769.09%
revenue TTM
1.76 Million
revenue per share TTM
0.38$
valuation ratios | |
|---|---|
| pe ratio | -3.72 |
| peg ratio | -0.18 |
| price to book ratio | -57.43 |
| price to sales ratio | 3.08 |
| enterprise value multiple | -0.96 |
| price fair value | -57.43 |
profitability ratios | |
|---|---|
| gross profit margin | 90.72% |
| operating profit margin | -769.09% |
| pretax profit margin | -998.53% |
| net profit margin | -992.95% |
| return on assets | -161.7% |
| return on equity | -755.61% |
| return on capital employed | -137.72% |
liquidity ratio | |
|---|---|
| current ratio | 11.03 |
| quick ratio | 10.81 |
| cash ratio | 9.54 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 496.22 |
| operating cycle | 726.11 |
| days of payables outstanding | 790.65 |
| cash conversion cycle | -64.54 |
| receivables turnover | 1.59 |
| payables turnover | 0.46 |
| inventory turnover | 0.74 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | -6.48 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.13 |
| cash per share | 0.69 |
| operating cash flow per share | -1.11 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -58.24 |
Frequently Asked Questions
When was the last time Cara Therapeutics, Inc. (NASDAQ:CARA) reported earnings?
Cara Therapeutics, Inc. (CARA) published its most recent earnings results on 14-11-2024.
What is Cara Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cara Therapeutics, Inc. (NASDAQ:CARA)'s trailing twelve months ROE is -755.61%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cara Therapeutics, Inc. (CARA) currently has a ROA of -161.7%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CARA's net profit margin stand at?
CARA reported a profit margin of -992.95% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CARA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 11.03 in the most recent quarter. The quick ratio stood at 10.81, with a Debt/Eq ratio of 0.00.